Published February 22, 2019 | Version v1

Immunotherapy and non-small cell lung cancers

Description

Lung cancer is the leading cause of cancer mortality, and non-small cell lung cancer (NSCLC) accounts for more than 85% of all lung cancers. Immunotherapy has brought a paradigm shift to the treatment of NSCLC. Immune checkpoint inhibitors have emerged as one of the main new therapeutic options for patients with advanced NSCLC. This brief review focuses on analyzing the biological rationale and early clinical data available concerning immunotherapeutic strategies, and more specifically, programmed cell death-1 (PD-1) inhibitors and programmed cell death-ligand 1 (PD-L1) inhibitors.

Files

fulltext.pdf

Files (238.7 kB)

Name Size
md5:bfaaa312b44fcfcd7e2ba3932fab1cee
238.7 kB Preview Download